The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2-Year Extension Study Supports Voclosporin to Treat Patients with Lupus Nephritis

2-Year Extension Study Supports Voclosporin to Treat Patients with Lupus Nephritis

August 23, 2021 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Voclosporin, a novel calcineurin inhibitor, reduces the activation of T cells and stabilizes podocytes, thereby reducing proteinuria. In late January, the U.S. Food & Drug Administration (FDA) approved voclosporin to treat adults with lupus nephritis, making it the first FDA-approved oral therapy for lupus nephritis available in the U.S.

You Might Also Like
  • Add-On Voclosporin Improves Outcomes in Lupus Nephritis
  • Voclosporin Promising for Lupus Nephritis
  • FDA Approves Belimumab & Voclosporin for Lupus Nephritis
Also By This Author
  • Innate Immune Response Enters Center Stage for Inflammatory Eye Disease

The treatment has a consistent dose-concentration relationship, so patients don’t need to undergo therapeutic drug monitoring. Also, it has an advantage over other drugs in its class because it has an improved lipid and glucose profile and no drug-drug interaction with mycophenolate mofetil (MMF).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although rheumatologists have heard about the benefits of voclosporin at past scientific meetings, the results of the AURORA 1 trial were not published until May 9 in The Lancet.1 The data come from the largest lupus nephritis clinical program to date, and the drug label includes much of the data from the publication. In the study, investigators report treatment with voclosporin in combination with MMF and low-dose steroids led to a clinically and statistically superior complete renal response rate when compared with MMF and low-dose steroids alone. Brad H. Rovin, MD, a nephrologist at the Ohio State University Wexler Medical Center, Columbus, and colleagues found the two treatment regimens had comparable safety profiles and concluded their findings represent an important advancement in the treatment of patients with active lupus nephritis.

The study describes how the addition of 23.7 mg of oral voclosporin twice daily increased complete renal response by 26% in the phase 2 Aurinia Urinary Protein Reduction Active—Lupus with Voclosporin (AURA-LV) trial and 18% in phase 3 AURORA 1 at one-year of treatment.2 The AURORA 1 study documented complete remission rates of 41%, with an odds ratio of 2.65 relative to placebo.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The extension study: Presented at the virtual EULAR 2021, June 2–5, the results from the interim analysis of the ongoing AURORA 2 extension study indicate that after two years of continued treatment, patients taking voclosporin maintain meaningful reductions in proteinuria, with no change in their mean estimated glomerular filtration rate (eGFR).3 The extension study documented a change in the urine protein/creatinine ratio from pre-treatment baseline to year 2 of -3.1 mg/mg for the voclosporin group and -2.1 mg/mg for the control group (P=0.0004).

Overall, patients experienced a small, early and expected decrease in mean eGFR in the voclosporin group in the first four weeks of treatment in AURORA 1, after which eGFR remained stable for two years. The researchers saw no unexpected adverse events in the AURORA 2 extension study and, thus, conclude the most recent data support a positive risk/benefit profile of voclosporin.

Speed of Remission Is Key

Robert Huizinga, PhD, RN, executive vice president of research at Aurinia Pharmaceuticals and corresponding author of The Lancet article emphasized the speed of remission in patients treated with voclosporin, which was twice that observed in the control group. Such remission should prevent ongoing, long-term kidney damage.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates, SLE (Lupus) Tagged With: kidney, Lupus nephritis, SLE Resource Center, voclosporin

You Might Also Like:
  • Add-On Voclosporin Improves Outcomes in Lupus Nephritis
  • Voclosporin Promising for Lupus Nephritis
  • FDA Approves Belimumab & Voclosporin for Lupus Nephritis
  • Study Finds Renal Arteriosclerosis Is Common in Lupus Nephritis Patients

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.